ZKP / USDT

ZKP / TRY

ZKP / USDC

G / USDT

G / TRY

SYN / USDT

SYN / USDC

BIFI / USDT

ZIL / IDR

ZIL / USDT

CHESS / USDC

CHESS / USDT

DATA / USDT

DF / USDC

ANKR / USDT

ANKR / TRY

HUMA / USDC

HUMA / TRY

DF / USDT

HUMA / USDT

PRECOT LIMITED

NGL FINE CHEM LIMITED

GOKALDAS EXPORTS LTD.

FAZE THREE LIMITED

LAKSHMI FIN IND CORP LTD

TIJARIA POLYPIPES LTD

CHETANA EDUCATION LIMITED

DUCON INFRATECHNOLOGIES L

GTL INFRA.LTD

ROSSELL TECHSYS LIMITED

V.L.INFRAPROJECTS LIMITED

GLOBAL PET INDUSTRIES LTD

SNEHAA ORGANICS LIMITED

INTERIORS & MORE LIMITED

BIOFIL CHEM & PHARMA LTD

JTL INDUSTRIES LIMITED

COOL CAPS INDUSTRIES LTD

TAPI FRUIT PROCESSING LTD

INNOMET ADVANCED MATERI L

SHRI HARE-KRI SPO IRON L

Click here to get full coverage on Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey  PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Click here to get full coverage on Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Biocon buys out Viatris and others from biosimilar subsidiary  Fierce Pharma

Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Click here to get full coverage on Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation - BW Healthcare World

Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation  BW Healthcare World

Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation - BW Healthcare World

Click here to get full coverage on Biocon Limited to integrate Biocon Biologics - The Pharma Letter

Biocon Limited to integrate Biocon Biologics  The Pharma Letter

Biocon Limited to integrate Biocon Biologics - The Pharma Letter

Click here to get full coverage on Viatris signs agreements with Biocon on $815m stake sale - Pharmaceutical Technology

Viatris signs agreements with Biocon on $815m stake sale  Pharmaceutical Technology

Viatris signs agreements with Biocon on $815m stake sale - Pharmaceutical Technology

Click here to get full coverage on Inclusive innovation: how Biocon brought biotech to all - Economist Impact

Inclusive innovation: how Biocon brought biotech to all  Economist Impact

Inclusive innovation: how Biocon brought biotech to all - Economist Impact

Click here to get full coverage on US proposal to halve biosimilar development costs for India's Biocon, top exec says - Reuters

US proposal to halve biosimilar development costs for India's Biocon, top exec says  Reuters

US proposal to halve biosimilar development costs for India's Biocon, top exec says - Reuters

Click here to get full coverage on Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360

Biocon Challenges Regeneron Over UK Retinal Pharma Patent  Law360

Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360

Click here to get full coverage on Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Biocon opens first US manufacturing facility in New Jersey  NJBIZ

Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Click here to get full coverage on Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion - Forbes

Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion  Forbes

Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion - Forbes

Click here to get full coverage on Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions - The Economic Times

Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions  The Economic Times

Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions - The Economic Times

Click here to get full coverage on Biocon Ltd up for five straight sessions - Business Standard

Biocon Ltd up for five straight sessions  Business Standard

Biocon Ltd up for five straight sessions - Business Standard

Click here to get full coverage on Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ  Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Click here to get full coverage on ‘We Have Been Forward Looking’: Biocon Biologics On Not Following The Keytruda Biosimilar Hype - Citeline News & Insights

‘We Have Been Forward Looking’: Biocon Biologics On Not Following The Keytruda Biosimilar Hype  Citeline News & Insights

‘We Have Been Forward Looking’: Biocon Biologics On Not Following The Keytruda Biosimilar Hype - Citeline News & Insights

Click here to get full coverage on Biocon Inaugurates First US Manufacturing Facility in Cranbury - New Jersey Business Magazine

Biocon Inaugurates First US Manufacturing Facility in Cranbury  New Jersey Business Magazine

Biocon Inaugurates First US Manufacturing Facility in Cranbury - New Jersey Business Magazine

Click here to get full coverage on Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion - Bloomberg

Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion  Bloomberg

Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion - Bloomberg

Click here to get full coverage on Amgen Expands US BPCIA Denosumab Litigation to include Biocon - Pearce IP

Amgen Expands US BPCIA Denosumab Litigation to include Biocon  Pearce IP

Amgen Expands US BPCIA Denosumab Litigation to include Biocon - Pearce IP

Click here to get full coverage on Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites  Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Click here to get full coverage on Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited  PR Newswire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

Click here to get full coverage on Watch Biocon Biologics CEO Discusses Merger and IPO Plans - Bloomberg

Watch Biocon Biologics CEO Discusses Merger and IPO Plans  Bloomberg

Watch Biocon Biologics CEO Discusses Merger and IPO Plans - Bloomberg

Click here to get full coverage on Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars  Yahoo Finance

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Click here to get full coverage on Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea  Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Click here to get full coverage on Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - Yahoo Finance

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options  Yahoo Finance

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - Yahoo Finance

Click here to get full coverage on Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact - Business Standard

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact  Business Standard

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact - Business Standard

Click here to get full coverage on SBI, ICICI Funds Said to Lead Bids in Oversubscribed Biocon Sale - Bloomberg

SBI, ICICI Funds Said to Lead Bids in Oversubscribed Biocon Sale  Bloomberg

SBI, ICICI Funds Said to Lead Bids in Oversubscribed Biocon Sale - Bloomberg

Click here to get full coverage on Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026 - Pearce IP

Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026  Pearce IP

Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026 - Pearce IP

Click here to get full coverage on Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars  Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Click here to get full coverage on Biocon to supply semaglutide to Ajanta for marketing in 26 countries - The Pharma Letter

Biocon to supply semaglutide to Ajanta for marketing in 26 countries  The Pharma Letter

Biocon to supply semaglutide to Ajanta for marketing in 26 countries - The Pharma Letter

Click here to get full coverage on Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review - The Economic Times

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review  The Economic Times

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review - The Economic Times

Click here to get full coverage on Biocon clarifies on reports of possible merger, IPO plans for Biocon Biologics - MSN

Biocon clarifies on reports of possible merger, IPO plans for Biocon Biologics  MSN

Biocon clarifies on reports of possible merger, IPO plans for Biocon Biologics - MSN

Click here to get full coverage on Biocon to merge biologics unit in $5.5 billion deal - Times of India

Biocon to merge biologics unit in $5.5 billion deal  Times of India

Biocon to merge biologics unit in $5.5 billion deal - Times of India

Click here to get full coverage on Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times

Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US  Ophthalmology Times

Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times

Click here to get full coverage on Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives  PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Click here to get full coverage on Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - lamag.com

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients  lamag.com

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - lamag.com

Click here to get full coverage on Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States  GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Click here to get full coverage on ‘You Control Your Destiny’ – CEO Mittal On Biocon’s US Manufacturing Push - Citeline News & Insights

‘You Control Your Destiny’ – CEO Mittal On Biocon’s US Manufacturing Push  Citeline News & Insights

‘You Control Your Destiny’ – CEO Mittal On Biocon’s US Manufacturing Push - Citeline News & Insights

Click here to get full coverage on Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara® - Yahoo! Finance Canada

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®  Yahoo! Finance Canada

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara® - Yahoo! Finance Canada

Click here to get full coverage on Biocon Biologics to Expand Biosimilar Oncology Portfolio, - GlobeNewswire

Biocon Biologics to Expand Biosimilar Oncology Portfolio,  GlobeNewswire

Biocon Biologics to Expand Biosimilar Oncology Portfolio, - GlobeNewswire

Click here to get full coverage on Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - Yahoo Finance

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases  Yahoo Finance

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - Yahoo Finance

Click here to get full coverage on Biocon secures global rights to biosimilar adalimumab - The Pharma Letter

Biocon secures global rights to biosimilar adalimumab  The Pharma Letter

Biocon secures global rights to biosimilar adalimumab - The Pharma Letter

Click here to get full coverage on Biocon Partners with Civica on Insulin Glargine Biosimilar; US$11 per Pen Pricing in California - Pearce IP

Biocon Partners with Civica on Insulin Glargine Biosimilar; US$11 per Pen Pricing in California  Pearce IP

Biocon Partners with Civica on Insulin Glargine Biosimilar; US$11 per Pen Pricing in California - Pearce IP

Click here to get full coverage on Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha

Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ)  Seeking Alpha

Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha

Click here to get full coverage on Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says  Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Click here to get full coverage on Budget 2026: Biocon shares gain after FM Nirmala Sitharaman announces ₹10,000 crore for Biopharma Shakti - CNBC TV18

Budget 2026: Biocon shares gain after FM Nirmala Sitharaman announces ₹10,000 crore for Biopharma Shakti  CNBC TV18

Budget 2026: Biocon shares gain after FM Nirmala Sitharaman announces ₹10,000 crore for Biopharma Shakti - CNBC TV18

Click here to get full coverage on Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; - Biocon

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%;  Biocon

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; - Biocon

Click here to get full coverage on Biocon eyes generic semaglutide market for 2026 - Endpoints News

Biocon eyes generic semaglutide market for 2026  Endpoints News

Biocon eyes generic semaglutide market for 2026 - Endpoints News

Click here to get full coverage on Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% EBITDA at Rs 829 Cr; Up 19%*; - Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% EBITDA at Rs 829 Cr; Up 19%*;  Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% EBITDA at Rs 829 Cr; Up 19%*; - Biocon

Click here to get full coverage on S&P Global upgrades Biocon Biologics credit rating To 'BB+' - The Economic Times

S&P Global upgrades Biocon Biologics credit rating To 'BB+'  The Economic Times

S&P Global upgrades Biocon Biologics credit rating To 'BB+' - The Economic Times

Click here to get full coverage on Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio  PR Newswire

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire

Click here to get full coverage on Why Samsung, Amgen, and Biocon are investing in US pharma facilities - Manufacturing Today

Why Samsung, Amgen, and Biocon are investing in US pharma facilities  Manufacturing Today

Why Samsung, Amgen, and Biocon are investing in US pharma facilities - Manufacturing Today

Click here to get full coverage on Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B - Pearce IP

Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B  Pearce IP

Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B - Pearce IP

Click here to get full coverage on In a push for pharma sector, FM Nirmala Sitharaman proposes ‘Biopharma Shakti’ with Rs 10K crore outlay - TradingView

In a push for pharma sector, FM Nirmala Sitharaman proposes ‘Biopharma Shakti’ with Rs 10K crore outlay  TradingView

In a push for pharma sector, FM Nirmala Sitharaman proposes ‘Biopharma Shakti’ with Rs 10K crore outlay - TradingView

Click here to get full coverage on Biocon other pharma stocks surge after FM Sitharaman proposes ₹10,000 crore for building biosimilars, biologics in Budget 2026 - Upstox

Biocon other pharma stocks surge after FM Sitharaman proposes ₹10,000 crore for building biosimilars, biologics in Budget 2026  Upstox

Biocon other pharma stocks surge after FM Sitharaman proposes ₹10,000 crore for building biosimilars, biologics in Budget 2026 - Upstox

Click here to get full coverage on Biocon clears US path for denosumab biosimilars - The Pharma Letter

Biocon clears US path for denosumab biosimilars  The Pharma Letter

BIOCON

Price Chart

Key Statistics

Technicals

About BIOCON

Latest News

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation - BW Healthcare World

Advanced Charts

Top Gainers

Top Losers